Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 223
interventional 190
Observational 28
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 75
Drug|Procedure 18
Biological 13
Biological|Drug|Other 12
Drug|placebo 11
Procedure 10
Biological|Drug 9
Drug|Other 6
Drug|Other|Procedure 5
Biological|Other 4
Other 4
Behavioral 2
Biological|Drug|Other|Procedure 2
Combination Product 2
Device|Drug 2
Drug|Procedure|Radiation 2
Behavioral|Other 1
Behavioral|Other|Procedure 1
Biological|Drug|Other|placebo 1
Biological|Drug|placebo 1
Biological|Drug|Procedure 1
Combination Product|Other|Procedure 1
Device 1
Device|Dietary Supplement|Drug 1
Device|Other 1
Diagnostic Test 1
Dietary Supplement 1
Drug|Other|placebo 1
Drug|Other|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 104
France 8
Germany 8
China 7
Netherlands 7
United States|Canada 5
Belgium 4
Canada 3
Denmark 3
United Kingdom 3
Korea, Republic of 2
NA 2
Sweden 2
Argentina|Canada|Germany|Poland|Sweden 1
Australia|France|Germany|Norway|United Kingdom 1
Belgium|France|Netherlands 1
Belgium|Germany|Poland|Russian Federation|Spain 1
Germany|Denmark|Finland|France|Norway|Sweden 1
India 1
Israel|New Zealand|China|United States|Australia|Poland|Russian Federation|South Africa|Switzerland|United Kingdom 1
Italy 1
Japan 1
Japan|Korea, Republic of 1
Norway 1
Norway|Sweden 1
Singapore 1
Slovakia|United States|Canada|Netherlands|United Kingdom 1
Spain 1
United States|Australia 1
United States|Australia|Austria|Belgium|Brazil|China|Czechia|Denmark|Finland|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Norway|Poland|Russian Federation|Spain|Sweden|Turkey 1
United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Greece|Italy|Netherlands|Norway|Poland|Portugal|Russian Federation|Slovakia|Spain|Sweden|Ukraine|United Kingdom 1
United States|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|Croatia|Czech Republic|Estonia|France|Greece|Hong Kong|India|Israel|Italy|Japan|Korea, Republic of|Latvia|Malaysia|Mexico|Peru|Poland|Portugal|Romania|Russian Federation|Slovenia|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Chile|Colombia|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Russian Federation|South Africa|Spain|Taiwan|Turkey|Ukraine 1
United States|Australia|Belgium|Italy|Poland|Spain|United Kingdom 1
United States|Australia|Canada|Denmark|Finland|France|Greece|Italy|Poland|South Africa|Spain|United Kingdom 1
United States|Australia|Canada|France|Spain|United Kingdom 1
United States|Belgium|Canada|Spain 1
United States|Brazil|Canada|Czechia|Hungary|Israel|Italy|Poland|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Canada|Japan|Korea, Republic of 1
United States|Canada|Korea, Republic of 1
United States|Canada|Netherlands 1
United States|France|Netherlands|Spain 1
United States|Germany 1
United States|Korea, Republic of 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 111
2 10
3 11
4 5
5 2
6 3
7 3
8 1
9 4
10 1
11 2
13 1
15 1
16 1
17 1
18 1
19 1
20 2
22 1
23 1
37 2
46 1
53 1
55 1
61 1
70 2
75 1
90 1
116 1
131 1
136 1
142 2
149 1
196 1
225 1
271 1
281 1
315 1
390 1
503 1
538 1
573 1
632 1
687 1

Phase

Phase Study_Count
Phase 2 66
Phase 1 50
Phase 3 31
Phase 1/Phase 2 18
N/A 16
Early Phase 1 6
Phase 2/Phase 3 3

Number of Arms

Number_of_Arms Count_of_Studies
1 93
2 54
3 15
4 4
5 3
6 1
7 1
NA 19

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3
Min. 17.00000 18.000 3.00 3.00000 4.00000 150.0000 30.0000
1st Qu. 17.50000 34.000 19.00 21.00000 30.00000 150.0000 152.0000
Median 24.50000 65.000 24.00 39.50000 52.00000 150.0000 581.0000
Mean 24.16667 1013.625 40.90 56.05556 79.73438 219.3333 624.8387
3rd Qu. 30.00000 114.750 38.25 62.50000 99.25000 254.0000 994.5000
Max. 32.00000 15000.000 474.00 264.00000 493.00000 358.0000 1873.0000

Trial Group Type

group_type Group_Count
Experimental 242
Active Comparator 23
NA 19
Other 10
Placebo Comparator 9
No Intervention 6

Intervention Model

intervention_model Study_Count
Single Group Assignment 102
Parallel Assignment 64
Sequential Assignment 10
NA 10
Crossover Assignment 4

Primary Purpose

primary_purpose Study_Count
Treatment 164
Diagnostic 7
Supportive Care 7
Other 5
Prevention 5
Basic Science 1
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 8
France 3
Germany 3
Belgium 2
Korea, Republic of 2
NA 2
Sweden 2
Austria 1
Canada 1
China 1
Egypt 1
India 1
Netherlands 1

Sites per Study

Site_count Study_Count
1 20
2 1
10 1
13 1
22 1
144 1
182 1
187 1
358 1

Enrollment Metrics

Measure Observational
Min 5.0000
1st Qu 43.7500
Median 93.0000
Mean 195.4286
3rd Qu 247.7500
Max 1200.0000

Observation Model

observational_model Study_Count
Cohort 12
Case-Only 7
Case-Control 5
NA 2
Ecologic or Community 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 18
Retrospective 6
NA 3
Cross-Sectional 1

Registries

Studies by Country

Country Study_Count
United States 2
Italy 1
Norway 1
Switzerland 1

Sites per Study

Site_count Study_Count
1 3
2 1
75 1

Enrollment Metrics

Measure Registries
Min 30.0
1st Qu 100.0
Median 193.0
Mean 200104.4
3rd Qu 200.0
Max 999999.0

Registry Model

observational_model Study_Count
Cohort 4
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 5

Follow-up

target_duration Study_Count
5 Years 2
10 Years 1
24 Months 1
80 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04034251 Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT04034251 Recruiting National Institutes of Health Clinical Center (CC) 2026-05-30
NCT03378128 Debulking Surgery in Ovarian Cancer https://ClinicalTrials.gov/show/NCT03378128 Recruiting Case Comprehensive Cancer Center 2020-08-31
NCT03304210 PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer https://ClinicalTrials.gov/show/NCT03304210 Recruiting University Hospital, Ghent 2020-09-21
NCT03287375 Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy - https://ClinicalTrials.gov/show/NCT03287375 Recruiting Odense University Hospital 2020-12-01
NCT03280511 Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients https://ClinicalTrials.gov/show/NCT03280511 Recruiting Odense University Hospital 2022-10-01
NCT03252938 Feasibility and Safety of IMP321 for Advanced Stage Solid Tumors https://ClinicalTrials.gov/show/NCT03252938 Active, not recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 2021-04-30
NCT03246321 PIPAC for Peritoneal Metastases of Colorectal Cancer https://ClinicalTrials.gov/show/NCT03246321 Completed Catharina Ziekenhuis Eindhoven 2019-10-01
NCT03245892 A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT03245892 Recruiting Memorial Sloan Kettering Cancer Center 2021-08-31
NCT03188432 Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03188432 Recruiting Wake Forest University Health Sciences 2020-11-01
NCT03127774 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma https://ClinicalTrials.gov/show/NCT03127774 Recruiting Columbia University 2022-05-31
NCT03073694 Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT03073694 Recruiting University of Kansas Medical Center 2020-07-31
NCT02948426 Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02948426 Recruiting National Institutes of Health Clinical Center (CC) 2022-04-01
NCT02891447 Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer https://ClinicalTrials.gov/show/NCT02891447 Active, not recruiting M.D. Anderson Cancer Center 2021-09-01
NCT02865811 Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02865811 Active, not recruiting Dana-Farber Cancer Institute 2021-02-28
NCT02855944 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients https://ClinicalTrials.gov/show/NCT02855944 Recruiting Clovis Oncology, Inc. 2022-06-30
NCT02840331 Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis https://ClinicalTrials.gov/show/NCT02840331 Recruiting University Hospital Tuebingen 2019-12-31
NCT02823860 Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies https://ClinicalTrials.gov/show/NCT02823860 Recruiting Hospices Civils de Lyon 2022-10-31
NCT02786524 Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy https://ClinicalTrials.gov/show/NCT02786524 Completed University of Michigan 2017-10-31
NCT02759588 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer https://ClinicalTrials.gov/show/NCT02759588 Recruiting Genelux Corporation 2020-07-31
NCT02758951 Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases https://ClinicalTrials.gov/show/NCT02758951 Recruiting Catharina Ziekenhuis Eindhoven 2024-08-01
NCT02739698 Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia https://ClinicalTrials.gov/show/NCT02739698 Completed Maimónides Biomedical Research Institute of Córdoba 2014-11-30
NCT02726997 Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) https://ClinicalTrials.gov/show/NCT02726997 Active, not recruiting M.D. Anderson Cancer Center 2021-07-30
NCT02713386 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02713386 Active, not recruiting NRG Oncology 2020-09-30
NCT02659241 Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02659241 Recruiting M.D. Anderson Cancer Center 2021-12-31
NCT02638051 Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT https://ClinicalTrials.gov/show/NCT02638051 Completed Galenic Research Institute Ltd 2014-12-31
NCT02606305 Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02606305 Active, not recruiting ImmunoGen, Inc. 2021-01-31
NCT02650986 Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 https://ClinicalTrials.gov/show/NCT02650986 Recruiting Roswell Park Cancer Institute 2021-06-20
NCT03172416 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT03172416 Recruiting National University Hospital, Singapore 2022-12-31
NCT03038100 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03038100 Active, not recruiting Hoffmann-La Roche 2020-03-30
NCT02571725 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer https://ClinicalTrials.gov/show/NCT02571725 Recruiting New Mexico Cancer Care Alliance 2020-02-29
NCT01970722 Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01970722 Recruiting City of Hope Medical Center 2021-05-19
NCT02520154 Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02520154 Recruiting M.D. Anderson Cancer Center 2020-07-31
NCT02475772 A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT02475772 Completed Ruhr University of Bochum 2018-05-31
NCT02463877 A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy https://ClinicalTrials.gov/show/NCT02463877 Active, not recruiting University of California, San Diego 2023-09-30
NCT02356471 Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery https://ClinicalTrials.gov/show/NCT02356471 Completed Wake Forest University Health Sciences 2016-10-31
NCT02320448 Treating Peritoneal Carcinomatosis With PIPAC https://ClinicalTrials.gov/show/NCT02320448 Completed Odense University Hospital 2017-08-31
NCT02316834 Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02316834 Active, not recruiting M.D. Anderson Cancer Center 2021-02-01
NCT02311907 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02311907 Completed Alliance for Clinical Trials in Oncology 2012-08-31
NCT02272790 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02272790 Active, not recruiting AstraZeneca 2018-12-13
NCT02231086 Adjuvant HIPEC in High Risk Colon Cancer https://ClinicalTrials.gov/show/NCT02231086 Active, not recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 2018-09-30
NCT02219893 Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial https://ClinicalTrials.gov/show/NCT02219893 Completed Oslo University Hospital 2016-12-10
NCT02179489 Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT02179489 Recruiting Zhejiang University 2019-10-31
NCT02158988 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT02158988 Active, not recruiting Charite University, Berlin, Germany 2020-10-31
NCT02151448 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies https://ClinicalTrials.gov/show/NCT02151448 Completed University of Pittsburgh 2019-02-18
NCT02142803 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02142803 Active, not recruiting National Cancer Institute (NCI) 2020-06-30
NCT02122185 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02122185 Recruiting University of Chicago 2021-02-25
NCT02111941 Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy https://ClinicalTrials.gov/show/NCT02111941 Active, not recruiting Mayo Clinic 2017-08-18
NCT01314105 BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01314105 Completed Boehringer Ingelheim 2013-07-31
NCT01313078 Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01313078 Completed National Institutes of Health Clinical Center (CC) 2011-09-30
NCT01312389 A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01312389 Completed Abramson Cancer Center of the University of Pennsylvania 2012-05-31
NCT02042430 Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02042430 Active, not recruiting National Cancer Institute (NCI) 2016-03-31
NCT02040142 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C https://ClinicalTrials.gov/show/NCT02040142 Recruiting Albert Einstein College of Medicine 2021-11-30
NCT02032485 Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer https://ClinicalTrials.gov/show/NCT02032485 Completed Jules Bordet Institute 2014-09-30
NCT02020707 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers https://ClinicalTrials.gov/show/NCT02020707 Recruiting Mayo Clinic 2020-10-03
NCT03834272 Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies https://ClinicalTrials.gov/show/NCT03834272 Active, not recruiting Lumicell, Inc. 2020-12-01
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) https://ClinicalTrials.gov/show/NCT01891344 Active, not recruiting Clovis Oncology, Inc. 2019-11-05
NCT01883297 “Re-Stimulated” Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01883297 Active, not recruiting University Health Network, Toronto 2023-06-30
NCT01882920 Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec) https://ClinicalTrials.gov/show/NCT01882920 Completed Regina Elena Cancer Institute 2012-06-30
NCT01853644 Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01853644 Active, not recruiting Northwestern University 2018-10-02
NCT01846611 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01846611 Completed Janssen Research & Development, LLC 2018-01-18
NCT01834469 Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients https://ClinicalTrials.gov/show/NCT01834469 Completed Jules Bordet Institute 2014-10-31
NCT01833832 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma https://ClinicalTrials.gov/show/NCT01833832 Completed National Institutes of Health Clinical Center (CC) 2018-08-09
NCT01767675 Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01767675 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT01764802 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer https://ClinicalTrials.gov/show/NCT01764802 Completed Ohio State University Comprehensive Cancer Center 2017-06-01
NCT01764789 Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer https://ClinicalTrials.gov/show/NCT01764789 Completed Ohio State University Comprehensive Cancer Center 2012-01-31
NCT01666444 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01666444 Completed Celgene 2016-07-31
NCT01652079 CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01652079 Completed Massachusetts General Hospital 2018-03-31
NCT02024841 Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT02024841 Completed The University of Hong Kong 2017-02-28
NCT01606241 Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01606241 Completed Mayo Clinic 2014-09-25
NCT01579812 Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients https://ClinicalTrials.gov/show/NCT01579812 Completed University of Michigan Rogel Cancer Center 2017-06-30
NCT01560533 Representation of the Body for Patients With Cancer https://ClinicalTrials.gov/show/NCT01560533 Completed Hospices Civils de Lyon 2013-01-31
NCT01536054 Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT01536054 Completed Roswell Park Cancer Institute 2015-04-21
NCT01524094 Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT01524094 Completed Uppsala University 2010-12-31
NCT01504256 Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas https://ClinicalTrials.gov/show/NCT01504256 Completed AIO-Studien-gGmbH 2017-03-31
NCT01504126 Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01504126 Completed M.D. Anderson Cancer Center 2019-08-15
NCT01478685 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01478685 Completed Celgene 2015-11-17
NCT01462890 Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT01462890 Active, not recruiting AGO Study Group 2018-11-30
NCT01443260 A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT01443260 Completed Genelux Corporation 2014-09-30
NCT01416038 Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01416038 Completed ImmunoVaccine Technologies, Inc. (IMV Inc.) 2013-05-31
NCT03348150 Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. https://ClinicalTrials.gov/show/NCT03348150 Recruiting The Netherlands Cancer Institute 2020-10-01
NCT01384253 Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy https://ClinicalTrials.gov/show/NCT01384253 Completed Orano Med LLC 2015-10-31
NCT01379482 Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer https://ClinicalTrials.gov/show/NCT01379482 Completed Uppsala University 2009-03-31
NCT01339650 Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01339650 Completed AbbVie 2017-11-30
NCT04370925 Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT04370925 Recruiting Affiliated Cancer Hospital & Institute of Guangzhou Medical University 2024-04-30
NCT04232384 Comparison of "Roll-over’ Technique With Standard Abdominal Paracentesis in Suspected Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT04232384 Recruiting Postgraduate Institute of Medical Education and Research 2021-11-15
NCT04231175 Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer https://ClinicalTrials.gov/show/NCT04231175 Recruiting The Netherlands Cancer Institute 2023-10-28
NCT04158349 Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer https://ClinicalTrials.gov/show/NCT04158349 Recruiting University of Utah 2023-01-30
NCT04107077 Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer https://ClinicalTrials.gov/show/NCT04107077 Recruiting University of Chicago 2023-06-01
NCT04047771 A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT04047771 Recruiting Sichuan Clover Biopharmaceuticals, Inc. 2021-05-31
NCT04029909 A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT04029909 Recruiting Lee’s Pharmaceutical Limited 2019-12-31
NCT03976999 Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers https://ClinicalTrials.gov/show/NCT03976999 Recruiting Institut du Cancer de Montpellier - Val d’Aurelle 2020-07-31
NCT03968406 Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers https://ClinicalTrials.gov/show/NCT03968406 Recruiting M.D. Anderson Cancer Center 2021-10-11
NCT03943173 Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery https://ClinicalTrials.gov/show/NCT03943173 Recruiting M.D. Anderson Cancer Center 2021-03-03
NCT03907527 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03907527 Recruiting Fred Hutchinson Cancer Research Center 2022-04-01
NCT03777943 Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis https://ClinicalTrials.gov/show/NCT03777943 Recruiting University Hospital, Ghent 2020-12-31
NCT03732781 Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC https://ClinicalTrials.gov/show/NCT03732781 Recruiting Oncoinvent AS 2022-12-31
NCT03699332 Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin https://ClinicalTrials.gov/show/NCT03699332 Recruiting Radboud University 2021-03-31
NCT03693248 Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03693248 Recruiting Seoul National University Hospital 2023-12-31
NCT03682744 CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) https://ClinicalTrials.gov/show/NCT03682744 Active, not recruiting Sorrento Therapeutics, Inc. 2020-09-30
NCT03663712 Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies https://ClinicalTrials.gov/show/NCT03663712 Recruiting Duke University 2021-03-01
NCT03635489 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03635489 Active, not recruiting Hoffmann-La Roche 2020-12-29
NCT03618758 Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 https://ClinicalTrials.gov/show/NCT03618758 Recruiting Seoul National University Bundang Hospital 2020-12-31
NCT03517852 Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC) https://ClinicalTrials.gov/show/NCT03517852 Active, not recruiting Mayo Clinic 2019-12-31
NCT03430700 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03430700 Recruiting University College, London 2020-11-16
NCT01264432 Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01264432 Completed National Cancer Institute (NCI) 2016-11-15
NCT01248962 Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01248962 Completed Memorial Sloan Kettering Cancer Center 2018-08-31
NCT01248273 Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission https://ClinicalTrials.gov/show/NCT01248273 Completed Memorial Sloan Kettering Cancer Center 2017-03-31
NCT01204749 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01204749 Completed Amgen 2013-03-31
NCT01188876 Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01188876 Completed Massachusetts General Hospital 2016-07-31
NCT01167712 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01167712 Active, not recruiting National Cancer Institute (NCI) 2015-12-01
NCT01105650 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer https://ClinicalTrials.gov/show/NCT01105650 Completed Masonic Cancer Center, University of Minnesota 2014-04-30
NCT01091428 Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer https://ClinicalTrials.gov/show/NCT01091428 Completed Takeda 2014-08-12
NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer https://ClinicalTrials.gov/show/NCT01061515 Active, not recruiting Washington University School of Medicine 2020-09-27
NCT01015118 LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer https://ClinicalTrials.gov/show/NCT01015118 Completed Boehringer Ingelheim 2013-04-01
NCT01010126 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer https://ClinicalTrials.gov/show/NCT01010126 Completed National Cancer Institute (NCI) 2017-03-13
NCT00989651 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00989651 Active, not recruiting National Cancer Institute (NCI) 2020-09-01
NCT00954174 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00954174 Active, not recruiting Gynecologic Oncology Group 2019-03-30
NCT00951496 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00951496 Active, not recruiting National Cancer Institute (NCI) 2016-01-11
NCT00857545 OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission https://ClinicalTrials.gov/show/NCT00857545 Completed Gynecologic Oncology Group 2015-09-30
NCT02833753 Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI https://ClinicalTrials.gov/show/NCT02833753 Recruiting University of Massachusetts, Worcester 2020-08-31
NCT03253133 Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC https://ClinicalTrials.gov/show/NCT03253133 Recruiting Institut du Cancer de Montpellier - Val d’Aurelle 2019-12-31
NCT00801320 Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00801320 Active, not recruiting Dana-Farber Cancer Institute 2020-08-31
NCT02903771 Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. https://ClinicalTrials.gov/show/NCT02903771 Completed Kazia Therapeutics Limited 2020-03-24
NCT03150992 EDMONd - Elemental Diet in Bowel Obstruction https://ClinicalTrials.gov/show/NCT03150992 Recruiting Royal Surrey County Hospital NHS Foundation Trust 2019-12-31
NCT02658214 Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02658214 Completed AstraZeneca 2019-11-14
NCT02578888 Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies https://ClinicalTrials.gov/show/NCT02578888 Completed Albert Einstein College of Medicine 2016-05-31
NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43) https://ClinicalTrials.gov/show/NCT03740165 Recruiting Merck Sharp & Dohme Corp. 2025-08-08
NCT04220827 Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer https://ClinicalTrials.gov/show/NCT04220827 Recruiting M.D. Anderson Cancer Center 2022-11-01
NCT03508570 Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT03508570 Recruiting M.D. Anderson Cancer Center 2021-01-01
NCT00769405 Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer https://ClinicalTrials.gov/show/NCT00769405 Completed UNICANCER 2015-12-31
NCT00719303 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00719303 Recruiting Gynecologic Oncology Group 2020-12-31
NCT00698451 A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers https://ClinicalTrials.gov/show/NCT00698451 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2010-10-31
NCT00683241 A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00683241 Completed Abramson Cancer Center of the University of Pennsylvania 2009-12-31
NCT00677079 Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00677079 Completed Sanofi 2008-12-31
NCT00666991 Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers https://ClinicalTrials.gov/show/NCT00666991 Completed CritiTech, Inc. 2013-05-31
NCT00616941 Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00616941 Completed Ludwig Institute for Cancer Research 2011-06-30
NCT00569673 Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00569673 Completed Gynecologic Oncology Group 2012-01-31
NCT00562640 Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) https://ClinicalTrials.gov/show/NCT00562640 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-12-31
NCT00520013 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors https://ClinicalTrials.gov/show/NCT00520013 Completed Dana-Farber Cancer Institute 2010-10-31
NCT00517621 Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire https://ClinicalTrials.gov/show/NCT00517621 Completed ARCAGY/ GINECO GROUP 2010-09-30
NCT00504257 Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma https://ClinicalTrials.gov/show/NCT00504257 Completed H. Lee Moffitt Cancer Center and Research Institute 2012-10-31
NCT00491855 Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT00491855 Completed M.D. Anderson Cancer Center 2012-12-31
NCT00489359 Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00489359 Completed Eli Lilly and Company 2010-02-28
NCT00483782 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00483782 Completed National Cancer Institute (NCI) NA
NCT00479817 Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00479817 Completed Amgen 2009-08-11
NCT00443196 Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas https://ClinicalTrials.gov/show/NCT00443196 Completed Pierian Biosciences NA
NCT00437502 A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00437502 Completed Duke University 2010-01-31
NCT00436657 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00436657 Completed M.D. Anderson Cancer Center 2011-04-30
NCT00436501 VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00436501 Completed National Cancer Institute (NCI) 2011-03-31
NCT00436215 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00436215 Completed National Institutes of Health Clinical Center (CC) 2014-06-26
NCT00391118 Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (“Sugar Pill”) https://ClinicalTrials.gov/show/NCT00391118 Completed Eli Lilly and Company 2010-04-30
NCT00388037 Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00388037 Completed National Cancer Institute (NCI) 2012-01-31
NCT00382811 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT00382811 Completed MEI Pharma, Inc. 2009-04-30
NCT00348699 AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00348699 Completed National Cancer Institute (NCI) 2013-01-31
NCT00332696 Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT00332696 Completed Novartis 2008-09-30
NCT00318370 Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy https://ClinicalTrials.gov/show/NCT00318370 Completed Morphotek 2010-02-28
NCT00317772 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00317772 Active, not recruiting M.D. Anderson Cancer Center 2020-09-04
NCT00314678 Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00314678 Completed University of California, Irvine NA
NCT00267696 Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00267696 Completed Ohio State University Comprehensive Cancer Center 2013-09-30
NCT00262990 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00262990 Completed Novartis 2010-02-28
NCT00262847 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00262847 Completed National Cancer Institute (NCI) 2010-11-30
NCT00217568 Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00217568 Completed Fred Hutchinson Cancer Research Center 2006-03-31
NCT00217555 Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00217555 Completed Fred Hutchinson Cancer Research Center 2006-02-28
NCT00216372 Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT00216372 Completed Ipsen 2008-10-31
NCT00191646 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy https://ClinicalTrials.gov/show/NCT00191646 Completed Eli Lilly and Company 2009-08-31
NCT00191607 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. https://ClinicalTrials.gov/show/NCT00191607 Completed Eli Lilly and Company NA
NCT00189566 Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse https://ClinicalTrials.gov/show/NCT00189566 Completed ARCAGY/ GINECO GROUP NA
NCT00189345 Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT00189345 Completed AGO Study Group NA
NCT00183794 Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma https://ClinicalTrials.gov/show/NCT00183794 Completed University of Southern California 2009-05-31
NCT00138242 Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00138242 Completed National Cancer Institute (NCI) NA
NCT00132067 Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00132067 Completed National Cancer Institute (NCI) 2006-08-31
NCT00126542 Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00126542 Completed National Cancer Institute (NCI) 2007-01-31
NCT00112086 OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 https://ClinicalTrials.gov/show/NCT00112086 Completed Japan Clinical Oncology Group 2007-02-28
NCT00108745 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00108745 Active, not recruiting Gynecologic Oncology Group 2022-01-01
NCT00103545 Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response https://ClinicalTrials.gov/show/NCT00103545 Completed AGO Study Group NA
NCT00093496 Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00093496 Completed National Cancer Institute (NCI) 2010-04-30
NCT00083122 Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00083122 Completed National Cancer Institute (NCI) 2010-07-31
NCT00075712 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00075712 Completed National Cancer Institute (NCI) NA
NCT00074867 Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00074867 Completed Pfizer NA
NCT00063401 Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00063401 Completed Eli Lilly and Company 2006-06-30
NCT00061308 Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00061308 Completed GlaxoSmithKline 2004-09-30
NCT00059618 PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00059618 Completed M.D. Anderson Cancer Center 2007-04-30
NCT00052962 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT00052962 Completed National Institutes of Health Clinical Center (CC) 2008-09-30
NCT00045175 UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00045175 Completed University Health Network, Toronto 2013-06-30
NCT00026091 Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00026091 Completed National Cancer Institute (NCI) 2004-03-31
NCT00006155 SU5416 and Carboplatin to Treat Ovarian Cancer https://ClinicalTrials.gov/show/NCT00006155 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001332 Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT00001332 Completed National Institutes of Health Clinical Center (CC) NA
NCT00035100 EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00035100 Completed Novartis 2003-06-30
NCT00004547 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy https://ClinicalTrials.gov/show/NCT00004547 Completed National Institutes of Health Clinical Center (CC) 2009-08-31
NCT00001569 Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT00001569 Completed National Institutes of Health Clinical Center (CC) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03364907 Clinical Pharmacology of Platinum-based Hyperthermic Intraperitoneal Chemotherapy https://ClinicalTrials.gov/show/NCT03364907 Active, not recruiting Radboud University 2019-06-08
NCT03253939 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric Cancer https://ClinicalTrials.gov/show/NCT03253939 Completed Hospices Civils de Lyon 2017-07-01
NCT03034850 Thrombin Generation and Platelet Activation in CRS/HIPEC https://ClinicalTrials.gov/show/NCT03034850 Completed Ziekenhuis Oost-Limburg 2016-07-31
NCT00086567 Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers https://ClinicalTrials.gov/show/NCT00086567 Completed National Institutes of Health Clinical Center (CC) NA
NCT02462564 Risk Factors for Early POCD in the Patients With PSM Undergoing CRS-HIPEC https://ClinicalTrials.gov/show/NCT02462564 Completed Wuhan University 2015-01-31
NCT02325648 The Intraoperative Physiologic Changes of Patients Under Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Prospective Observational Study https://ClinicalTrials.gov/show/NCT02325648 Completed Yonsei University 2016-04-30
NCT01957852 FloSeal in CRS and HIPEC https://ClinicalTrials.gov/show/NCT01957852 Completed Maisonneuve-Rosemont Hospital 2013-03-31
NCT01932125 An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01932125 Recruiting Hoffmann-La Roche 2020-11-30
NCT01788995 BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT01788995 Completed Hoffmann-La Roche 2018-10-11
NCT01697488 An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA) https://ClinicalTrials.gov/show/NCT01697488 Completed Hoffmann-La Roche 2019-09-27
NCT01617382 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed https://ClinicalTrials.gov/show/NCT01617382 Recruiting Universitaire Ziekenhuizen Leuven 2025-01-31
NCT01545063 CAre of Patients With PArenteral Nutrition At Home https://ClinicalTrials.gov/show/NCT01545063 Completed KU Leuven 2013-04-30
NCT01538498 Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer https://ClinicalTrials.gov/show/NCT01538498 Completed National Cancer Center, Korea 2012-11-30
NCT01372787 Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01372787 Active, not recruiting Gynecologic Oncology Group 2014-01-31
NCT01366183 Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01366183 Active, not recruiting Gynecologic Oncology Group 2019-12-31
NCT04341337 Link of Interest and Training Model https://ClinicalTrials.gov/show/NCT04341337 Completed Centre de l’arthrose, Paris 2020-04-06
NCT04307654 Lactate and Complications in Cytoreduction Surgery for Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT04307654 Completed Hospital General Universitario de Castellón 2014-06-30
NCT04252560 The Impact of Gut Microbiota in Anastomoses Insufficiency After Resection and Direct Anastomosis for Colorectal Cancer. https://ClinicalTrials.gov/show/NCT04252560 Recruiting Uppsala University Hospital 2021-01-31
NCT04108936 Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses https://ClinicalTrials.gov/show/NCT04108936 Recruiting University of Regensburg 2020-06-30
NCT03931304 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2) https://ClinicalTrials.gov/show/NCT03931304 Completed Hospices Civils de Lyon 2018-07-31
NCT03798132 Peritoneal Carcinomatosis Extent Evaluation: Radiologic, Laparoscopic and Pathologic. https://ClinicalTrials.gov/show/NCT03798132 Recruiting South Egypt Cancer Institute 2019-06-11
NCT03593681 Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy https://ClinicalTrials.gov/show/NCT03593681 Completed Boston Scientific Corporation 2020-02-14
NCT01080521 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy https://ClinicalTrials.gov/show/NCT01080521 Completed Gynecologic Oncology Group 2012-01-31
NCT00997633 Single-photon Emission Computed Tomography (SPECT) to Predict Peritoneal Chemotherapy https://ClinicalTrials.gov/show/NCT00997633 Completed Uppsala University 2004-08-31
NCT00897442 Collecting Tumor Samples From Patients With Gynecological Tumors https://ClinicalTrials.gov/show/NCT00897442 Completed Gynecologic Oncology Group 2016-01-31
NCT03100708 Register Study of Patients With Peritoneal Carcinomatosis Treated With PIPAC (Pressurized Intra-peritoneal Aerosol-Chemotherapy) https://ClinicalTrials.gov/show/NCT03100708 Recruiting University of Leipzig 2021-04-30
NCT00004909 Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer https://ClinicalTrials.gov/show/NCT00004909 Completed Northwestern University 2002-11-30
NCT00502177 Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin https://ClinicalTrials.gov/show/NCT00502177 Completed M.D. Anderson Cancer Center 2018-08-29

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03124394 Prospective Intraperitoneal Chemotherapy in Carcinomatosis Cohort Study https://ClinicalTrials.gov/show/NCT03124394 Recruiting Kantonsspital Winterthur KSW 2020-12-31
NCT02082886 HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry https://ClinicalTrials.gov/show/NCT02082886 Completed Edward-Elmhurst Health System 2020-01-31
NCT02073500 Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies https://ClinicalTrials.gov/show/NCT02073500 Recruiting Oslo University Hospital 2017-01-31
NCT02012699 Integrated Cancer Repository for Cancer Research https://ClinicalTrials.gov/show/NCT02012699 Recruiting University of Nebraska 2099-12-31
NCT04122937 Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer. https://ClinicalTrials.gov/show/NCT04122937 Completed University of Pisa 2018-06-01